Showing posts with label castration-resistant prostate cancer. Show all posts
Showing posts with label castration-resistant prostate cancer. Show all posts

Friday, October 12, 2012

FDA approves Enzalutamide (XTANDI Capsules)



Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of castration-resistant prostate cancer  currently in phase 3 clinical trials. Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth. In August of 2012, the U.S. Food and Drug Administration approved enzalutamide (see structure) for the treatment of castration-resistant prostate cancer......
 
Approved Drugs > Enzalutamide (XTANDI Capsules)